Similar articles

• Maintenance chemotherapy in non-small cell lung cancer.

  Eaton KD, Martins RG. Eaton KD, et al. J Natl Compr Canc Netw. 2010 Jul;8(7):815-21. doi: 10.6004/jnccn.2010.0058. J Natl Compr Canc Netw. 2010. PMID: 20679540 Review.
• Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.

  Bartminski W. Bartminski W. Rev Port Pneumol. 2009 May-Jun;15(3):555-9; author reply 560-6. Rev Port Pneumol. 2009. PMID: 19526635 English, Portuguese. No abstract available.
• Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed.

  Hanna NH. Hanna NH. Clin Lung Cancer. 2004 Apr;5 Suppl 2:S75-9. doi: 10.3816/clc.2004.s.007. Clin Lung Cancer. 2004. PMID: 15117429 Review.
• Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.

  Nadler E, Forsyth M, Satram-Hoang S, Reyes C. Nadler E, et al. J Thorac Oncol. 2012 Jan;7(1):212-8. doi: 10.1097/JTO.0b013e3182307f33. J Thorac Oncol. 2012. PMID: 22124474
• Factors driving the choice of the best second-line treatment of advanced NSCLC.

  Maione P, Rossi A, Bareschino MA, Sacco PC, Schettino C, Falanga M, Barbato V, Ambrosio R, Gridelli C. Maione P, et al. Rev Recent Clin Trials. 2011 Jan;6(1):44-51. doi: 10.2174/157488711793980192. Rev Recent Clin Trials. 2011. PMID: 20868346 Review.